Overview

Obesity is a prevalent condition and is often associated with adipose tissue dysfunction. Increased understanding of obesity and its metabolic complications has given rise to novel anti-obesity therapeutic approaches targeting adipose tissue, including cell and Gene Therapy. Protheragen offers a tailor-made one-stop service for anti-obesity cell therapy development based on our extensive expertise and well-established cell therapy development platform. Our dedicated team of professionals is well-versed in the complexities of obesity and facilitates all stages of anti-obesity cell therapy development and pre-clinical studies through innovative and rigorous research.

Driving the Development of Innovative Anti-Obesity Therapies Through Tailored Solutions

We are at the forefront of cell therapy development and are committed to advancing this novel technology. Our team gathers many research scientists with deep academic backgrounds and practical experience in obesity, allowing us to meet our clients' research needs more precisely. Specific services include the following:

Anti-Obesity Cell Therapy Development

We genetically modify or directly transplant a variety of cells into animal models and evaluate the efficacy and reliability of such therapies. Gene editing strategies include viral and non-viral-based transfection and other precision gene editing techniques.

• Development of adipocyte-based anti-obesity therapies
  It is found that gene editing of white adipocytes to develop into brown fat-like cells improves glucose tolerance and insulin sensitivity and increases energy expenditure in post-transplant obese mice. We genetically modify adipocytes and analyze the physiological conditions of animal models after transplantation to assess the therapeutic efficacy of this therapy.

• Development of Stem Cell-based Anti-Obesity Therapies
  • Mesenchymal stem cell (MSC)
    As a pluripotent stem cell, MSC has the ability to self-renew and differentiate into cell types such as adipocytes. It has a variety of promising properties, including migration to multiple tissues, regulation of proliferation and activation of the immune system, and the potential to differentiate into multiple lineages. MSC therapy is currently being developed as a promising strategy for the treatment of obesity. We develop MSC-based (adipose tissue-derived mesenchymal stem cell, human umbilical cord-derived mesenchymal stromal cell, etc.) anti-obesity therapies and evaluate their effects on obesity, metabolic disorders, etc.
  • Induced pluripotent stem cells (hiPSC)
    In addition to this, we process hiPSC, including gene editing, differentiation, etc., and investigate the impact of this strategy on obesity.

• Development of Chimeric Antigen Receptor (CAR) T-Cell Therapy
  CAR-T cells targeting urokinase plasminogen activator receptor (uPAR) are found to have therapeutic activity in a diet-induced obesity model by promoting weight loss and improving glucose homeostasis. We genetically modify T cells in vitro to target specific loci. The transgenic T cells are then transferred to animals and evaluated for their therapeutic potential.

Preclinical Studies of Therapies

• Obesity Models: Animal models play a critical role in elucidating the molecular mechanisms of obesity and evaluating the safety and efficacy of new anti-obesity cell therapies. We offer a variety of animal models to support our clients' studies of anti-obesity cell therapies.
  • Diet-induced animal models
  • Gene editing models
  • Other types of models
• Evaluation of cell therapy: Based on state-of-the-art facilities and cutting-edge technology, we perform pharmacodynamic studies, pharmacokinetics studies, bioanalysis, and safety assessments of anti-obesity cellular therapies. We analyze fat metabolism, histology, metabolism-related gene expression, etc., to assess the effect of cell transplantation on obesity and the potential mechanism of action.

  Pharmacodynamics Study

  Pharmacokinetics Study

  Bioanalysis

  Safety Assessment

Workflow

Our flexible and innovative anti-obesity cell therapy development program is a great option to accelerate your research.

Applications

• Type 2 diabetes therapy study: Obesity increases the risk of developing type 2 diabetes. Anti-obesity cell therapies may have great potential in treating this disease as well.
• Metabolic syndrome therapy research: Metabolic syndrome is closely related to obesity and overweight. Anti-obesity cell therapy research provides valuable information for the development of metabolic syndrome therapies.
• Preventive therapy research: The development of anti-obesity cell therapy helps promote the research of personalized obesity prevention strategies.

Advantages

• We provide tailored solutions to specific research needs and complete all experiments from anti-obesity cell therapy development, and animal model construction to preclinical studies.
• Each of our experimental processes is meticulously carried out to ensure the accuracy and consistency of data in anti-obesity cell therapy development projects.
• Our experienced researchers are available to answer any questions our clients may have during their anti-obesity studies.

Our Services

Publication Data

Frequently Asked Questions

What is the potential of gene editing for cell therapy development?

Gene editing is a novel approach to generating cells with enhanced therapeutic potential. New genetic engineering tools and techniques are emerging to better achieve this goal, including improving the function of these cells, enhancing their viability, immunomodulatory properties, etc. Transgenic cells are found to be more efficient in vivo in treating metabolic disorders and reducing obesity symptoms compared to wild-type MSC.

What are the advantages of stem cells?

Stem cells are a class of cells with multidirectional differentiation potential and self-renewal, and are divided into various types, including induced pluripotent stem cells (iPSCs), MSCs, and others. Based on the goodness of stem cells, they have important applications in understanding the molecular mechanisms of obesity, developing new effective anti-obesity drugs, and developing stem cell-based therapies. For example, MSC-based cell therapy has been shown to reduce body weight and improve glucose tolerance in obese mice.

Protheragen offers a flexible anti-obesity cell therapy development service based on deep research into obesity, careful cell selection, and a deep understanding of potential therapeutic mechanisms. We aim to accelerate your obesity therapeutic research with efficient project turnaround. Please feel free to contact us for more information and to discuss further experimental processes.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Anti-Obesity Antibody Therapy Development
• Anti-Obesity Gene Therapy Development
• Anti-Obesity Nanotherapy Development
• Anti-Obesity Small Molecule Drug Development
• Anti-Obesity Tissue Engineering Therapy Development